期刊文献+

DNA免疫吸附治疗系统性红斑狼疮疗效观察及护理体会 被引量:1

Clinical effect of DNA immunoadsorption therapy in treatment of systemic lupus erythematosus and related nursing management
下载PDF
导出
摘要 目的探讨应用DNA免疫吸附治疗系统性红斑狼疮(SLE)的疗效及护理体会。方法 21例SLE患者进行48次免疫吸附治疗,治疗过程中针对患者心理、饮食、血管通路、不良反应和并发症等多方面实施护理干预。结果免疫吸附治疗后,21例患者纳差和乏力症状改善,免疫吸附治疗2周后复查血清抗双链DNA抗体水平(ds-DNA)较治疗前显著下降(P<0.01)。治疗期间主要不良反应为2例血小板减少。结论 DNA免疫吸附是治疗SLE的重要手段之一,合理的护理措施是保障治疗顺利的关键。 Objective To observer the clinical effect of DNA immunoadsorption therapy in treatment of systemic lupus erythematosus ( SLE) and to summarize the nursing management. Methods A total of 21 SLE patients undergoing 48 times of DNA immunoadsorption therapy were included in this study. Nursing measures were provided mainly focusing on psychological states, diet, vascular access ,side reaction and complication of patients. Results The symptom such as anorexia and fatigue were improved in all 21 SLE patients after DNA immunoadsorption therapy. The serum level of anti-ds- DNA autoantibody was decreased 2 weeks after treatment compared with that before treatment (P 〈0. 01) . The main side reaction was thrombocytopenia, which was reported in two cases during observation period. Conclusion DNA immunoadsorption therapy is an important way of treating SLE, and proper nursing measures should be applied to ensure the therapeutic effect.
出处 《中西医结合护理(中英文)》 2016年第7期22-24,共3页 Journal of Clinical Nursing in Practice
关键词 DNA免疫吸附 系统性红斑狼疮 护理干预 DNA immunoadsorption therapy systemic lupus erythematosus nursing intervention
  • 相关文献

参考文献3

二级参考文献27

  • 1董全文,王连永,俞耀庭,吴晨.几种类风湿关节炎吸附剂的制备及吸附性能比较[J].南开大学学报(自然科学版),2006,39(5):79-85. 被引量:1
  • 2Ferndndez-Nebro A, Marsal S, Chatham W,et al. Sys- temic Lupus Erythematosus: Genomics, Mechanisms, and Therapies. Cli Dev Immunol, 2012,16 : 4-5.
  • 3Ramos-casals M, Sanz I, Bosch X, et al. B-cell-depleting therapy in systemic lupus erythematosus[J]. American J Med,2012,125(4) :327-336.
  • 4Arbuckle MR, McClain MT, Rubertone MV,et al. De- velopment of autoantibodies before the clinical onset of systemic lupus erythematosus[J]. N Engl J Med, 2003, 349(16):1 526-1 533.
  • 5Lo MS, Tsokos GC. Treatment of systemic lupus ery- thematosus:new advances in targeted therapy[J]. Ann N Y Acad Sci,2012,1 247:138-152.
  • 6Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus ery- thematosus. Arthritis Rheum, 2002,46 (10) : 2 673- 2 677.
  • 7Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized,double- blind,phase II/III systemic lupus erythematosus evalu- ation of rituximab trial[J]. Arthritis Rheum, 2010,62 (1) :222-233.
  • 8Furie R,Looney J,Rovin B,et al. Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase iii lu- nar study[J]. Ann Rheum Dis, 2010,69 : 549.
  • 9Ramos-Casals M,Diaz-Lagares C,Khamashta MA. Rit- uximab and lupus: good in real life, bad in controlled trials-comment on the article by Lu et al[J]. Arthritis Rheum, 2009,61(9):1 281-1 282.
  • 10Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Ritux- imab in systemic lupus erythematosus:a systematic re- view of off-label use in 188 cases[J]. Lupus, 2009,18 (9) :767-776.

共引文献23

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部